Top Markets
Coin of the day
Recordati Industria Chimica e Farmaceutica S.p.A. Recordati Industria Chimica e Farmaceutica S.p.A.

Recordati Industria Chimica e Farmaceutica S.p.A.

REC
Peringkat dalam Saham #1793
Recordati Industria Chimica e Farmaceutica S.p.A., together with its... Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, researches, develops, produces, and sells pharmaceuticals in Italy, the United States, Spain, France, Germany, Russia, Ukraine, Turkey, Portugal, North Africa, and internationally. It operates through Specialty and Primary Care; and Rare Diseases segments. The company develops Maapliv for maple syrup urine disease; Isturia for endogenous Cushing’s syndrome; Cystadrops treatment of the ocular manifestations of cystinosis; Carbaglu for hyperammonemia due to n-acetyl glutamate synthase deficiency; Qarziba for neuroblastoma patients and patients with relapsed or refractory neuroblastoma; and Fotivda for renal cell carcinoma. It also develops Sylvant for idiopathic multicentric castleman diseases; Caphosol for oral mucositis; ENJAYMO for hemolysis in adults with cold agglutinin disease; Zanidip, Zanipress, Vazkepa, and Logimax for hypertension; Urorec and Avodart for symptoms of benign prostatic hyperplasia; and Livazo for dyslipidemia; Combodart/Duodart; Seloken for angina pectoris, myocardial infarction and cardiac rhythm disorders, as well as hypertension and functional heart disorders. In addition, the company offers Procto-Glyveno for internal and external hemorrhoids; Polydexa, Isofra, and Otofa for ear, nose and throat infections; Isturisa, for Cushing’s syndrome; Normosang, human hemin; Juxtapid, homozygous familial hypercholesterolemia;Ledaga, mycosis fungoides, T-cell cutaneous lymphoma;Tergynan, an anti-infective for gynecological infections; CitraFleet and Phosphosoda as bowel cleansers; Lomexin for gynecological and dermatological infections; Hexaspray, treatments for the oral cavity; Magnesio Supremo, a dietary supplement; Reaglia for schizophrenia; Eligard for hormone-dependent prostate cancer; and pasireotide in Phase II trial for patients with post-bariatric hypoglycemia, as well as other products. The company was founded in 1926 and is headquartered in Milan, Italy.
Harga Saham
$62.39
Kapitalisasi Pasar
$12.69B
Perubahan (1 hari)
-0.19%
Perubahan (1 tahun)
6.33%
Negara
IT
Perdagangan Recordati Industria Chimica e Farmaceutica S.p.A. (REC)

Kategori

Harga REC dengan kapitalisasi pasar B
Recordati Industria Chimica e Farmaceutica S.p.A. Recordati Industria Chimica e Farmaceutica S.p.A.
REC
$62.39
Kapitalisasi pasar dari Recordati Industria Chimica e Farmaceutica S.p.A.(REC)
Kapitalisasi Pasar: $12.69B
Per August 2026, Recordati Industria Chimica e Farmaceutica S.p.A. memiliki kapitalisasi pasar sebesar $12.69B. Ini menjadikan Recordati Industria Chimica e Farmaceutica S.p.A. sebagai perusahaan 1793rd paling bernilai di dunia menurut data kami. Kapitalisasi pasar adalah nilai total saham beredar dari perusahaan publik dan biasanya digunakan untuk mengukur seberapa besar nilai sebuah perusahaan.
Riwayat kapitalisasi pasar Recordati Industria Chimica e Farmaceutica S.p.A. dari 1995 hingga 2026
REC dibandingkan dengan 5 teratas stocks paling populer
Harga REC Aset B Pasar B Hasil
Recordati Industria Chimica e Farmaceutica S.p.A. Recordati Industria Chimica e Farmaceutica S.p.A.
$26,458.68 $12.69B
$5.383T +42,307.32%
Recordati Industria Chimica e Farmaceutica S.p.A. Recordati Industria Chimica e Farmaceutica S.p.A.
$21,740.53 $12.69B
$4.423T +34,745.19%
Recordati Industria Chimica e Farmaceutica S.p.A. Recordati Industria Chimica e Farmaceutica S.p.A.
$20,447.80 $12.69B
$4.160T +32,673.24%
Recordati Industria Chimica e Farmaceutica S.p.A. Recordati Industria Chimica e Farmaceutica S.p.A.
$18,004.86 $12.69B
$3.663T +28,757.75%
Recordati Industria Chimica e Farmaceutica S.p.A. Recordati Industria Chimica e Farmaceutica S.p.A.
$14,210.10 $12.69B
$2.891T +22,675.61%